Researcher:
Yurtaydın, Süleyman Cihan

Loading...
Profile Picture
ORCID

Job Title

Faculty Member

First Name

Süleyman Cihan

Last Name

Yurtaydın

Name

Name Variants

Yurtaydın, Süleyman Cihan

Email Address

Birth Date

Search Results

Now showing 1 - 10 of 34
  • Placeholder
    Publication
    Estimating the prevalence of hepatitis delta infection among foreign-born adults with chronic hepatitis B in the United States
    (ELSEVIER, 2022) Wong, Robert; Brosgart, Carol; Wong, Steven; Feld, Jordan; Glenn, Jeffrey; Hamid, Saeed Sadiq; Moraras, Kate; Ward, John; Wedemeyer, Heiner; Gish, Robert G.; N/A; Yurtaydın, Süleyman Cihan; Faculty Member; N/A; School of Medicine; N/A; 189330
    N/A 
  • Placeholder
    Publication
    Functional cure with lonafarnib-based therapy in chronic hepatitis delta
    (Wiley, 2022) Yurdcu, Esra; Gumussoy, Mesut; Keskin, Onur; Zeybel, Mujdat; Idilman, Ramazan; Bozdayi, Mithat; Choong, Ingrid; Glenn, Jeffrey; Gençdal, Genco; Yurtaydın, Süleyman Cihan; Akyıldız, Murat; Zeybel, Müjdat; Doctor; Faculty Member; Faculty Member; 0000-0001-5440-4623; N/A; School of Medicine; School of Medicine; School of Medicine; Koç University Hospital; N/A; 189330; 123080; 214694
    N/A
  • Placeholder
    Publication
    Editorial: natural history of hepatitis delta virus-induced liver disease - less severe today but still needs attention
    (Wiley, 2021) N/A; N/A; N/A; Gençdal, Genco; Zeybel, Müjdat; Yurtaydın, Süleyman Cihan; Doctor; Faculty Member; Faculty Member; N/A; School of Medicine; School of Medicine; Koç University Hospital; N/A; 214694; 189330
    N/A
  • Placeholder
    Publication
    Chronic hepatitis delta with normal alt and hepatitis d viremia
    (Elsevier, 2022) Arici, Sena; Palom, Adriana; Gumussoy, Mesut; Idilman, Ramazan; Esteban, Rafael; Buti, Maria; Gençdal, Genco; Zeybel, Müjdat; Yurtaydın, Süleyman Cihan; Doctor; Faculty Member; Faculty Member; N/A; School of Medicine; School of Medicine; Koç University Hospital; N/A; 214694; 189330
    N/A
  • Placeholder
    Publication
    Co-infection with HBV and HDV increases immune exhaustion when compared to HBV monoinfection
    (Wiley, 2022) Khanam, Arshi; Abutaleb, Ameer; Byambabaatar, Sumiya; Dashdorj, Naranjargal; Kottilil, Shyam; Akyıldız, Murat; Yurtaydın, Süleyman Cihan; Faculty Member; Faculty Member; School of Medicine; School of Medicine; 123080; 189330
    N/A
  • Placeholder
    Publication
    Treatment endpoints for chronic hepatitis D
    (Wiley) Metin, Olga; N/A; N/A; Zeybel, Müjdat; Yurtaydın, Süleyman Cihan; Faculty Member; Faculty Member; School of Medicine; School of Medicine; 214694; 189330
    Management of chronic hepatitis D (CHD) has entered a new era. In this new era, the virus entry inhibitor bulevirtide has received conditional approval as a treatment for compensated CHD. Three phase 3 studies with two new compounds are ongoing for the treatment of CHD. In this context, surrogate markers of treatment efficacy have been well defined for chronic hepatitis B (CHB) (7) and chronic hepatitis C (8) but not for CHD. The aim of this review is to give a perspective on treatment endpoints in CHD. For this, we took guidance from CHB studies and tried to make suggestions which differed according to finite versus prolonged treatment durations and also took into account the different characteristics of the new compounds.
  • Placeholder
    Publication
    Before saying goodbye some recollection and some humble suggestions
    (Lippincott Williams & Wilkins, 2022) N/A; Yurtaydın, Süleyman Cihan; Faculty Member; School of Medicine; 189330
  • Placeholder
    Publication
    Estimating hepatitis delta prevalence among high risk populations in the United States: a systematic review
    (WILEY, 2022) Wong, Robert J.; Brosgart, Carol L.; Wong, Steven S.; Feld, Jordan J.; Glenn, Jeffrey; Moraras, Kate; Hamid, Saeed S.; Ward, John W.; Wedemeyer, Heiner; Yurdaydin, Cihan; Gish, Robert G.; N/A; Yurtaydın, Süleyman Cihan; Faculty Member; N/A; School of Medicine; N/A; 189330
    N/A
  • Placeholder
    Publication
    Effect of HBV-HDV co-infection on HBV-HCC co-recurrence in patients undergoing living donor liver transplantation
    (Springer, 2020) Baskiran, Adil; Akbulut, Sami; Şahin, Tevfik Tolga; Koc, Cemalettin; Karakas, Serdar; Ince, Volkan; Yılmaz, Sezai; N/A; Yurtaydın, Süleyman Cihan; Faculty Member; School of Medicine; 189330
    Purpose: To evaluate the effect of hepatitis D virus (HDV) on hepatitis B virus-hepatocellular carcinoma (HBV-HCC) co-recurrence in patients undergoing living donor liver transplantation (LDLT) for HBV alone or HBV-HDV coinfection. Methods: Between 2002 and 2019, 254 HBV-HCC patients underwent LDLT. The patients were divided into two groups after the application of the exclusion criteria: HBV-HCC (Group B; n = 163) and HBV-HDV-HCC (Group D; n = 31). First, the B and D groups were compared in terms of demographic and clinical parameters. Second, patients with (n = 16) and without (n = 178) post-transplant HBV-HCC co-recurrences were grouped and compared in terms of the same parameters. Results: Although the risk of HBV-HCC co-recurrence in group D was 4.99-fold higher than in group B, the risk of HBV recurrence alone in group D was 12.5-fold lower than in group B. The AFP (OR = 4.4), Milan criteria (beyond; OR = 18.8), and HDV (OR = 8.1) were identified as the independent risk factors affecting post-transplant HBV-HCC co-recurrence. The Milan criteria (OR = 2.1) and HBV-HCC co-recurrence (OR = 10.9) were identified as the risk factors affecting post-transplant mortality. HBV-HCC co-recurrence developed in 26.5% of patients in Group B and 100% in Group D (OR = 40; p = 0.001). HCC recurrence alone developed in 10% of patients without HBV recurrence in group B and 0% of patients without HBV recurrence in group D (OR = 5.7). Conclusion: This study showed that the risk of HBV recurrence alone was reduced by 12.5-fold in the presence of HDV; however, the HCC recurrence occurred in all patients with HDV when HBV recurrence developed.
  • Placeholder
    Publication
    Treatment discontinuation in HBeAG-negative chronic Hepatit B is a viable option in non-cirrhotic genotype d chronic Hepatitis B patients
    (Wiley, 2019) Sah, Fatma Tugce; Keskin, Onur; Yurdcu, Esra; Yilmaz, Yusuf; Karakaya, Muhammet Fatih; Kartal, Aysun; Bozdayi, Mithat; Idilman, Ramazan; N/A; Yurtaydın, Süleyman Cihan; Faculty Member; School of Medicine; Koç University Hospital; 189330
    N/A